Financing ·
Vivos Therapeutics exchanged $2,861,270 of principal from its Secured Promissory Note with Streeterville Capital for…
VVOSVivos Therapeutics, Inc.
Vivos Therapeutics exchanged $2,861,270 of principal from its Secured Promissory Note with Streeterville Capital for 11,445,080 shares of common stock at an average price of $0.25 per share on September 2, 2026. The transaction reduced the note's outstanding balance to $3.7 million and increased issued and outstanding shares from approximately 22.2 million to 33.6 million. This issuance represents approximately 34% of the post-transaction common stock base. Vivos Therapeutics operates in the medical device industry, developing implantable neuromodulation devices for sleep-disordered breathing.